Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture

Exclusion Criteria

• •Participants previously exposed to collagenase Clostridium histolyticum for treatment of Dupuytren's disease (Xiaflex, Xiapex®).
• •Participants who have received other treatments for advanced Dupuytren's disease, including surgery (fasciectomy or fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study treatment.
• •Participants with a chronic muscular, neurological, or neuromuscular disorder that affects the hands, or other medical condition which in the Investigator's opinion will make the participant unsuitable for enrollment in the study.
• •Participants who have a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition (eg, testing positive for tuberculosis \[TB\] or Coronavirus disease 2019 \[COVID-19\], etc), or history of alcoholism or drug abuse, which in the Investigator's opinion, would make the participant unsuitable for enrollment in the study.
• •Participants who have a known allergic response to collagenase or any other excipient of CNT201 or Xiaflex.
• •Participants who have received a doxycycline or tetracycline derivative within 14 days before the beginning of the study (tetracycline derivatives may inhibit the collagenolytic activity of mammalian collagenase homologs).
• •Participants who have received an anticoagulant (except aspirin ≤150 mg/day) within 7 days before the start of the study.
• •Female participants who are nursing or pregnant, or plan to become pregnant during the study treatment stage of the study.
• •Participants who have been treated with any investigational drug within 30 days of first dose of study treatment.